Invasive versus non-invasive diagnosis of renal bone disease

Current Opinion in Nephrology and Hypertension

Volumn 6, Issue 4, 1997, Pages 333-348

  Fournier, Albert ^a   Oprisiu, Roxana ^a   Said, Said ^a   Sechet, Anne ^a   Ghazali, Abderahman ^a   Marié, Annick ^a   El Esper, Isabelle ^a   Brazier, Michel ^a   Achard, Jean Michel ^a   Morinière, Philippe ^a  

^a AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER;

ANALYTIC METHOD; BONE BIOPSY; BONE DISEASE; BONE REMODELING; BONE TURNOVER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; HISTOLOGY; HUMAN; HUMAN CELL; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY DISEASE; MORPHOMETRICS; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW;

EID: 8544283056     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199707000-00006     Document Type: Review

References (70)

1. Schmidt-Gayk H, Roth HJ, Becker S, Reichel H, Boneth HG, Knuth UA: Non invasive parameters of bone metabolism. Curr Opin Nephrol Hypertens 1995, 4:334-338.
2. Parfitt AM: Bone histomorphometry: standardization of nomenclature, symbols and units. Bone and mineral 1988, 4:1-5.
3. Garcia Carasco M, Gruson M, de Vernejoul MC, Denne A, Miravet L: Osteocalcin and bone histomorphometric parameters in adults without bone disease. Calcif Tissue Int 1988, 42:13-17.
4. Sherrard DJ, Oh S, Maloney N, Andress O, Coburn J: Renal osteodystrophy: classification, cause and treatment. In Clinical Disorders of Bone and Mineral Metabolism. Edited by Frame B, Potts JJ. Amsterdam Excepta Medica, 1983:254-259.
5. Vedi S, Compston JE, Webb A, Tighe JR: Histomorphometric analysis of bone biopsies from the iliac crest of normal British Subjects. Metab Bone Dis Rel Res 1982, 4:231-236.
6. Andress DL, Maloney NA, Coburn JW, Endres DB, Sherrard DJ: Osteomalacia and aplastic bone disease in aluminium related osteodystrophy. J Clin Endocr Metab 1987, 65:11-16.
7. Weinstein RS: Clinical use of bone biopsy in disorders of bone and mineral metabolism. Edited by Coe FL and Favus MJ. New York: Raven Press; 1992:455-474.
8. Steiniche T, Moseldike L, Christensen MS, Melsen F: A histomorphometric determination of iliac bone remodelling in patients with recurrent renal stone formation and idiopathic hypercalciuria. APMIS 1989, 97:309-316.
9. Parfitt AM: The physiologic and pathogenetic significance of bone histomorphometry. In Disorders of Bone and Mineral Metaboloism. Edited by Coe F, Favus M. New York, Raven Press, 1992:475-498.
10. Qi Q, Monier-Faugere MC, Geng Z, Malluche H: Predictive value of serum levels for bone turn-over in patients on chronic maintenance dialysis. Am J Kidney Dis 1995, 26:622-631.
11. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y: Relationship between intace 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis 1995, 26:836-844.
12. Atik A, Ghazali A, Achard JM, Rida Z, Brazier M, Leflon, Gueris J, Moriniere Ph, Sari Z, Fournier A: La depletion relative en vitamine D native: un facteur de risque potential chez l'hémodialysé algérien de lésions radiologiques d'hyperparathyroïdie et d'ostéomalacie, indépendant de la calcitriolémie? (In French). Nephrologie (In press).
13. Kaye M, Hodsman AB, Malinowsky L: Staining of bone aluminum: use of acid solochrome azurine. Kidney Int 1990, 37:1142-1147.
14. Malluche HM, Monier-Faugère MC: The role of bone biopsy in the management of patients with renal osteodystrophy. J Am Soc Nephrol 1994, 4:1631-1642.
15. Van de Vyver FL, Visser WJ, D'Haese PC, de Broe M: Iron overload and bone disease in chronic dialysis patients. Nephrol Dial Transplant 1990, 5:781-787.
16. Fournier A, Said S, Ghazali A, Sechet A, Ezaitouni F, Marié A, Westeel FP, Morinière P, Boudailliez B: Adynamic bone disease in uremia: which clinical significane? Advances in Nephrology. Edited by Grünfeld JP. Chicago: Mosby Year Book (In press). This article shows that the clinical significance of ABD in patients never exposed to aluminium is quite uncertain, the only possible consequences being a higher risk of metastatic calcification in CAPD patients, of osteopenia in ABD induced in adults by very low phosphate diet and of stunted growth in children when ABD is induced by bolus administration of calcitriol. It reports preliminary results showing that the risk of osteopenia, metastatic calcification, hypercalcaemia and hyperphosphataemia is the lowest in dialysis patients never exposed to aluminium when the plasma intact PTH levels are between one-and two-fold the upper limit of normal.
17. Sebert JL, Marié A, Guéris J, Hervé MA, Leflon P, Garabedian M, Smadja A. Fournier A: Assessment of the aluminium overload and of its possible toxicity in asymptomic uremic patients: evidence for a depressve effect on bone formation. Bone 1985, 6:373-375.
18. Morrissey E, Rothstem M, Mayor G, Slatopolsky E: Suppression of parathyroid hormone secretion by aluminium. Kidney Int 1983, 23:699-704.
19. Berland Y, Charbet M, Henry JF, Toga M, Olmer M: Aluminum overload of the parathyroid glands in haemodialyzed patients with hyperparathyroidism: effect on bone remodeling. Nephrol Dial Transplant 1988, 3:417-422.
20. Felsenfeld AJ, Rodriguez M, Coleman M, Ross D, Llac F: Desferrioxamine therapy in hemodialysis patients with aluminium-associated bone disease. Kidney Int 1989, 35:1371-1378.
21. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ: Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 1993, 44:860-866.
22. Zins B, Zingraff J, Basile C, Petitclerc T, Bardin T, Drüeke T: Tumoral calcification in hemodialysis patients. Possible role of aluminum intoxication. Nephron 1992, 60:260-267.
23. Geffriaud C, Allinne E, Page B, Zingraff J, Jucquel JP, Bardin T, Drüeke TB: Decrease of tumor-like calcification in uremia despite aggravation of secondary hyperparathyroidism: a case report. Clin Nephrol 1992, 38:158-161.
24. Johnson WJ, MaCarthy JT, Van Murden JA, Sterioff B, Grant CG, Kao PC: Results of subtotal parathyroidectomy in hemodialysis patients. Am J Med 1988, 84:23-32.
25. Ackrill P, Ralston AJ, Day JP, Hodge KC: Successful removal of aluminum from a patient with dialysis aluminum. Lancet 1980, ii:692-693.
26. Hercz G, Sherrard DJ, Chau W, Pei Y: Aplastic osteodystrophy: follow up after 5 years [Abstract]. J Am Soc Nephrol 1994, 5:851.
27. Stein MS, Packhan DK, Ebeing PR, Warck JD, Becker GJ: Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 1996, 28:512-522.
28. Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis SA, Billis A: Evaluation of the factors associated with osteopenia in hemodialysis patients [Abstract]. Nephrol Dial Transplant 1996, 11:A38.
29. Piraino B, Chen T, Cooperstein L, Segre GV, Puschett J: Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1988, 30:57-62.
30. Lobåo R, Carvalho A, Cuppari L, Ajzen H: Low turn-over bone disease detected by bone densitometry in predialysis chronic renal failure patients [Abstract]. J Am Soc Nephrol 1996, 11:1793.
31. Said S: A la recherche du taux optimal de PTH intacte chez les hémodialysés chroniques en terme de risque d'ostéopénie et de calcifications métastatiques [in French]. Mémoire de DIS - CHU d'Amiens: Amiens Medical School; 1997.
32. Hardy P, Morinière P, Marié A, El Esper N, Fournier A: Dialysis granulomatosis: a new cause of relative hypoparathyroidism with hypercalcemia compatible with adynamic bone disease. XIIIh Congress of International Society of Nephrology, Madrid 1995, 1995:415.
33. Hedri F, Sechet A, Rasolombololona M, Abighanem OA, Oprisiu R, Fournier A: Control of hyperphosphatemia in dialyzed patients. Ital J Miner Electrolyte Metab 1996, 10:1-14.
34. Fournier A, Morinière P, Oprisiu R, Yverneau-Hardy P, Ghazali A, Boudailliez B: 1α OH vitamin D3 derivatives in the treatment of renal bone disease: justification and optimal modalities of administration. Nephron 1995, 71:254-283.
35. Coburn JN, Frazao J: Calcitriol in the management of renal osteodystrophy. Semin Dial 1996, 9:316-326.
36. Drüeke T, Zingraff J: The dilemma of parthyroidectomy in chronic renal failure. Curr Opin Nephrol Hypertens 1994, 3:386-395.
37. Boelaert JR, de Locht M: Side effects of desferrioxamine in dialysis patients. Nephrol Dial Transplant 1993, 8(suppl 1):43-46.
38. Reichel H, Drüeke T, Ritz H: Bony complications in chronic renal failure. In Oxford Textbook of Nephrology. edited by Cameron S, Davison A, Grünfeld JP, Kerr DNS, Ritz H. Oxford: Oxford medical publication: 1992:1365-1389.
39. D'Haese PC, Couttenye MM, De Broe ME: Diagnosis and treatment of aluminum bone disease. Nephrol Dial Transplant 1996, 11(suppl 3):74-79. This paper reviews the procedures for the diagnosis of aluminium low bone turnover disease with advice slightly different from that formerly expressed in the European Consensus, especially with regard to the threshold value of basal plasma aluminium for suspecting a risk of aluminium overload. This value is 30 μg/l (i.e. ≠ 1 μmol/l) instead of 2 μmol/l, provided there is no iron deficiency which per se may increase the basal level of aluminium.
40. Pei T, Hercz G, Greenwood C, Sherrard D, Segre D, Manuel A, Saiphoo C, Fenton S: Non invasive prediction of aluminium bone disease in hemo and peritoneal dialysis patients. Kidney Int 1992, 41:1374-1382.
41. Brown R, Aston JP, Weeks I, Woodhead JS: Circulating intact PTH measured by a two sites immunochemoluminometric assay. J Clin Endocrinol Metab 1987, 65:407-414.
42. Cohen Solal ME, Sebert JL, Boudailliez B, Mariè A, Morinière B. Gueris J, Bouillon R, Fournier A: Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991, 73:516-524.
43. Fournier A, Oprisiu R, Yverneau-Hardy P, Marié A, Ghazali A, Morinière P, El Esper N: What is the optimal range of intact PTH in uremic patients? Ital J Mineral Electrolyte Metab 1995, 9:95-100.
44. Gerakis A, Hutchinson AJ, Apostolou T, Freemont AJ, Billis A: Biochemical markers for non invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis. Nephrol Dial Transplant 1996, 11:2430-2438. This paper reports the predictive value of PTH and bone gamma carboxyglutomic acid peptide in 114 adult dialysis patients with aluminium overload (>25%) in 66 of them. A PTH > 200pg/ml predicted osteitis fibrosa with a positive predictive value of 78% whereas a PTH <65 pg/ml predicted ABD with a positive predictive value of 45%. A plasma bone gamma carboxyglutamic acid peptide ≥ 50 mg/ml or ≥ 20 mg/ml did not increase the positive predictive value. In the 40 patients without histological deposits of aluminium, a PTH >200 pg/ml predicted osteitis fibrosa with a greater positive predictive value of 97%.
45. Quarles LD, Lobaugh B, Murphy G: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992, 75:145-150.
46. Mathias R, Salusky IB, Harman W: Renal bone disease in pediatric and young adult patients in hemodialysis in a children hospital. J Am Soc Nephrol 1993, 3:1938-46.
47. Salusky IB, Ramirez IA, Oppenheim W, Gales B, Segre GV, Goodman WG: Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994, 45:253-258.
48. Salusky IB, Ramirez JA, Belin TH, Goodman W: Pulse calcitriol therapy: a prospective randomized trial [Abstract]. J Am Soc Nephrol 1994, 5:855.
49. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Favrey IT: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. B Med J 1995, 310:358-363.
50. Bianchi ML, Colantonio G, Campanini F, Rossi R, Valenti G, Ortolani S, Buccianti G: Calitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 1994, 9:1595-1599.
51. Lafage H, Combe C, Fournier A, Aparicio M: Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 1992, 42:1217-1225.
52. Lafage H, Blanchetier V, Delmas Y, Lassem C, de Precigout V, Combe C, Aparicio M: Effect of long term low phosphorus intake on bone histology in non dialyzed uremic patients [Abstract]. J Am Soc Nephrol 1996, 11:1793.
53. Hutchinson AJ, Whitehouse RW, Boulton HF, Adams J, Mawer FB, Fremont TJ, Gokal R: Correlation of bone histology with parathyroid hormone, vitamin D3 and radiology in end stage renal failure. Kidney Int 1993, 44:1071-1077.
54. Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, Torres A: Adynamic bone disease and negative aluminium staining in predialysis patients: prevalence and evolution after dialysis. Nephrol Dial Transplant 1994, 9:517-522.
55. Fournier A, Oprisiu R, El Esper N, Morinière P: Optimal plasma concentration of intact PTH in predialysis patients [Reply]. Nephrol Dial Transplant 1995, 10:2376-2378.
56. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Felsenfeld A, Rodriguez M. Bone disease in predialysis hemodialysis and CAPD patients. Evidence for a better bone response to PTH. Kidney Int 1995, 47:1434-1442.
57. Schmidt-Gayk H, Drücke T, Ritz E: Non invasive circulating indications of bone metabolism in uremic patients: can they replace bone biopsy? Nephrol Dial Transplant 1996, 11:415-418.
58. Withold W, Degenhardt S, Castelli D, Heins M, Grabensee B: Monitoring of osteoblast activity with an immunoradiometric assay for determination of bone alkalie phosphatase mass concentration in patients receiving renal transplants. Clin Chim Acta 1994, 225:137-146.
59. Couttenye MM, D'Haese PC, Van Hoff VO, Lemoniatou E, Goodman W, Verpooten GA, de Broe ME: Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996, 11:1065-1072. This paper shows that low BAP measured using a electrophoretic procedure is diagnostic of ABD in a population exposed to aluminium phosphate binder and without liver disease. It fails to show that the predictioin of ABD with BAP is significantly better than with intact PTH alone or with TAP.
60. Hamdy NAT, Risteli J, Risteli L: Serum type I procollagen peptide: a non-invasive index of bone formation in patients on hemodialysis? Nephrol Dial Transplant 1994, 9:511-516.
61. Ureǹa P, Ferreira A, Kung V, Morieux C, Drüeke T, de Vernejoul MC: Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Miner Res 1995, 10:932-939.
62. Niwa T, Shiobara K, Hamada T: Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. Clin Chim Acta 1995, 235:33-40.
63. Ferreira A, Ureǹa P, Ang KS et al: Relationship between serum β2-microglobulin, bone histology and dialysis membranes in uraemic patients. Nephrol Dial Transplant 1995, 10:1701-1707.
64. Coen G, Ballantini P, Bonucci E, Sardella D, Taggi F: Bone markers in the diagnosis of low turn-over osteodystrophy in haemodialysis patients [Abstract]. Nephrol Dial Transplant 1996, 11:A41. This study evaluates the predictive value for the diagnosis of ABD and normal bone versus osteitis fibrosa of not only intact PTH but also of TAP and BAP, osteocalcin, deoxypyridinoline, C terminal cross-linked peptide of collagen I and TRAP in a population of 41 Italians slighly exposed to aluminium phosphate binders. It shows that the two best parameters are intact PTH and BAP, their combination predicting low turnover bone disease with a positive predictive value of 73% and high turnover disease with a positive predictive value of 97%.
65. Ureǹa P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC: Plasma total versus bone alkaline phosphatase as markers of bone turn-over in hemodialysis patients. J Am Soc Nephrol 1996, 7:506-512. This paper shows that BAP measured using the Ostase® kit is higher in patients with high BFR than in those with normal BFR. Unfortunately only one patient out of 17 had low BFR.
66. Sherrard DJ: Aluminium. Much ado about something. N Engl J Med 1991, 324:558-559.
67. Fournier A, Morinière P, Coevoet B, Makdassi R, Sebert J: Prevention and medical treatment of hyperparathyroidism secondary to renal failure In the adult. In Advance in Nephrology. Edited by Hamburger J. Chicago, USA: Year book Medical Publisher, 1982, 11:241-276.
68. Hümpfner A Hummel S, Schulz W: Diagnosis and therapy of aluminium overload. Results of a representative enquiry in the West Germany dialysis centers in 1989-90 [Abstract, in German]. 12 Donau Symposium für Nephrologie Bamberg, Juni 1994, 1994:71.
69. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon Barré M, d'Amour P: Accumulation of a non (1-84) molecular form of parthyroid hormone detected by intact PTH assay in renal failure importance in the interpretation of PTH values. J Clin Endocinol Metab 1996, 81:3923-3929. This article shows that the Allegro Kit of the Nichols institute used for the determination of intact PTH measures not only true 1 84 PTH but also another molecular form that, like C terminal fragments, accumulates in uraemia. To have the same concentration of true 1-84 PTH in uraemic patients as in non-uraemic patients, the concentration measured should be 1.57-fold higher. This suggests that dialysis patients with their plasma intact PTH in the optimal range of one- to two-fold the upper limit of normal and normal BFR actually have normal secretion of PTH and therefore no skeletal resistance to the remodelling effect of endogenous PTH.
70. Massry SG, Coburn JW, Lee D, Kleeman CR: Skeletal resistance to PTH in renal failure: studies in 105 human subjects. Ann Intern Med 1973, 78:357-364.